89BIO INC.
0.053919
USD
(+0.17%)
03/06/2025 - 15:35
Open 15 min delayed data - NASDAQ Stocks
| Open: | 0.053400 |
| Change: | +0.000090 |
| Volume: | 0 |
| Low: | 0.053389 |
| High: | 0.058639 |
| High / Low range: | 0.005250 |
| Type: | Stocks |
| Ticker: | ETNB |
| ISIN: |
89BIO INC. news, videos and press releases
For more news please use our advanced search feature.
89BIO INC. - More news...
89BIO INC. - More news...
- 03/03/2025 - 21:05 89bio to Participate in the Leerink Partners Global Healthcare Conference
- 02/27/2025 - 21:05 89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
- 02/06/2025 - 21:05 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 02/03/2025 - 13:00 89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- 01/29/2025 - 03:31 89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
- 01/27/2025 - 21:12 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- 01/13/2025 - 13:00 89bio Provides Business Update and Outlook for 2025
- 12/19/2024 - 21:05 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 11/29/2024 - 18:30 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 11/26/2024 - 21:05 89bio to Participate in the 7th Annual Evercore HealthCONx Conference
- 11/15/2024 - 13:05 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
- 11/13/2024 - 04:58 89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
- 11/12/2024 - 21:01 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- 11/07/2024 - 21:05 89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
- 11/05/2024 - 21:05 89bio to Participate in the UBS Global Healthcare Conference
- 10/15/2024 - 12:30 89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
- 10/11/2024 - 20:05 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 09/30/2024 - 20:05 89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
- 09/19/2024 - 20:03 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 09/16/2024 - 20:05 89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
- 08/29/2024 - 12:00 89bio to Participate in Upcoming Investor Conferences
- 08/09/2024 - 20:05 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 08/07/2024 - 12:00 89bio Appoints Francis Sarena as Chief Operating Officer
- 08/05/2024 - 20:05 89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
- 08/05/2024 - 12:00 89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
- 07/12/2024 - 20:05 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 06/14/2024 - 20:05 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 05/22/2024 - 20:05 89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
- 05/14/2024 - 12:00 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
- 05/10/2024 - 20:05 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
